Situation Far From Ideal But EU Network Will Survive Brexit
Brexit undoubtedly will cause some short-term disruption to the EU medicines regulatory network but the network will survive without the UK. That’s according to former European Medicines Agency head Thomas Lönngren. Meanwhile, the timetable for relocating the EMA is likely to be finalized in a few days’ time – as are the criteria for hosting the agency when it moves from London.
You may also be interested in...
Massive Reallocation of UK Rapporteurships Likely As EMA Plans For Future; UK’s Interim Role Uncertain
If Brexit means the UK no longer plays a part in the EU drug regulatory system, responsibility for the ongoing oversight of almost one in four of all the human medicines that have ever been approved under the centralized procedure will have to be reassigned from the UK to other member states. What Brexit means for the UK’s role as a key player in the regulatory system in the meantime is the subject of speculation.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.